As generic semaglutide enters the Canadian market, new patient, competitive and access dynamics are beginning to emerge. This Insight Brief explores how generic semaglutide is beginning to reshape the GLP-1 market in Canada.

Using data from June 2026, this IQVIA Insight Brief examines early patient uptake and switching patterns, the evolving competitive landscape, and the generic products expected to enter the market. It also highlights key considerations for stakeholders navigating reimbursement, access, pricing and commercialization in this rapidly developing post-exclusivity environment.